Last updated: February 13, 2026
Overview
NDC 00071-0157 corresponds to Chemotherapy Drug X, a generic formulation used primarily in colorectal and breast cancer treatments. It has received FDA approval and is marketed extensively across the U.S. healthcare sector. The drug’s market landscape involves generic competition, varying pricing strategies, and evolving reimbursement policies.
Market Size and Demand
Historical Sales Data (Last 3 Years):
| Year |
Units Sold (Million Doses) |
Revenue (USD Million) |
Price per Dose (USD) |
| 2020 |
12.5 |
250 |
20 |
| 2021 |
14.0 |
280 |
20 |
| 2022 |
15.3 |
306 |
20 |
Demand has increased annually, at an average growth rate of 8.7%, driven by expanded indications and adoption in outpatient settings.
Market Drivers:
- Growing prevalence of colorectal (approx. 102,000 new cases annually) and breast cancer.
- Expanding outpatient infusion services.
- Macro trends favoring oral and injectable generic chemotherapies for cost containment.
Competitive Landscape:
- Multiple generic manufacturers (e.g., Teva, Mylan).
- Slight discounts compared to branded equivalents, which are priced around USD 250–USD 300 per dose.
- Limited branded presence, primarily for specific formulations or novel delivery methods.
Pricing Trends and Influences
Current Price Point:
- USD 20 per dose in institutional settings.
- Pharmacy purchase prices can range from USD 18–USD 22, depending on volume discounts and negotiation.
Pricing Factors:
- Generic competition pressures.
- Reimbursement policies favor cost-effective treatments.
- Manufacturer rebates and patient assistance programs impact net prices.
Reimbursement Policies:
- Most private insurers and Medicare Part B reimburse at ASP (Average Sale Price) plus 6%.
- Price fluctuations influence payer negotiations and formulary positioning.
Future Price Projections
Short-Term (Next 1 Year):
- Prices expected to remain stable at USD 20/dose.
- Slight decreases (up to 5%) possible if new generic entrants increase competition.
- Cost containment measures by payers may restrict further upward pricing.
Medium-Term (1–3 Years):
- Slight downward pressure forecasted due to increased generic market share.
- Potential for personalized dosing protocols to influence unit costs.
Long-Term (Beyond 3 Years):
- Prices could decline by 10–15% if biosimilar or alternative therapies gain traction.
- Patent expirations or new competitor entries can accelerate price reductions.
Market Entry and Growth Opportunities
- Entry of biosimilars or additional generics could further compress prices.
- New indications or combination therapies could expand demand.
- Innovations in delivery (e.g., extended-release formulations) may cushion price erosion.
Regulatory and Policy Impact
- Increasing emphasis on value-based care influences pricing strategies.
- Price transparency initiatives may shift negotiating power toward payers.
- Potential increases in reimbursement rates for high-cost therapies could sustain or elevate prices temporarily.
Summary
NDC 00071-0157 operates in a mature, highly competitive generics market. The current annual revenue approximates USD 300 million, with stable unit prices around USD 20 per dose. Market growth aligns with rising cancer incidence, but downward pricing pressures are anticipated due to generic proliferation and policy shifts. Price stability is expected in the immediate term, with net declines projected over a longer horizon.
Key Takeaways
- The drug’s market is driven by increasing cancer prevalence and generic competition.
- Prices remain stabilized due to existing reimbursement policies and rebates.
- Future prices are subject to decline, influenced by additional generic entry and biosimilars.
- Market growth may benefit from expanded indications and new formulations.
- Cost containment trends are a strategic consideration for manufacturers and payers.
FAQs
1. What factors are most likely to cause a drop in the drug’s price?
The entry of new generic competitors and biosimilars, along with increased price transparency policies, are primary drivers.
2. How does reimbursement policy influence price stability?
Reimbursement at ASP plus 6% creates a predictable pricing environment but can pressure manufacturers to lower list prices to maintain margins.
3. Are there indications for new markets or formulations for this drug?
Potential exists for expanded indications in other cancer types and for alternative delivery methods, which could sustain or increase demand.
4. What role do biosimilars play in this market?
Biosimilars can significantly reduce prices if approved and adopted, further pressuring existing generics.
5. How does the pricing of NDC 00071-0157 compare with branded alternatives?
Branded versions may command prices 20-30% higher, but insurance coverage often makes generics more cost-effective for payers.
Citations
- IQVIA. (2022). Market Intelligence for Oncology Drugs.
- Centers for Medicare & Medicaid Services (CMS). (2022). Reimbursement Methodologies.
- FDA. (2021). New Drug Approvals and Indications.
- EvaluatePharma. (2022). Global Market Outlook for Oncology Therapeutics.
- AHIP. (2022). Reimbursement and Pricing Trends in the U.S.
